PRINCETON, N.J. / May 21, 2025 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in the Bernstein 41st Annual Strategic Decisions Conference on Wednesday, May 28, 2025.
The company will take part in a fireside chat beginning at 3:30 p.m. ET.
Investors and the general public are invited to listen to the session by visiting http://investor.bms.com. An archived edition of the session will be available following its conclusion.
About Bristol Myers Squibb: Transforming Patients’ Lives Through Science
At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what’s possible for the future of medicine and the patients we serve. For more information, visit us at BMS.com and follow us on LinkedIn, X, YouTube, Facebook and Instagram.
| Last Trade: | US$53.95 |
| Daily Change: | -0.26 -0.48 |
| Daily Volume: | 7,135,701 |
| Market Cap: | US$110.060B |
December 08, 2025 December 03, 2025 December 01, 2025 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
